Shuttle Pharmaceuticals Holdings Inc. has entered a research agreement with Georgetown University focused on the evaluation of the company's lead histone deacetylase 6 (HDAC6) inhibitor candidate, SP-2-225, evaluating the antitumor effect of the combination of SP-2-225 and radiation therapy in a syngeneic breast cancer model.
A research group at Washington University School of Medicine has released animal data showing restriction of tumor growth with a novel mRNA therapeutic delivered in nanoparticles based on Altamira Therapeutics Ltd.’s Semaphore delivery platform.
The role that mitochondrial inner membrane protein (IMMT) has in regards to clinicopathology and tumor microenvironment in breast cancer in unclear. IMMT is part of the mitochondrial contact site and cristae organizing system (MICOS) and its function is to maintain mitochondrial integrity.
Fibrogen Inc. has synthesized inhibitors of lysine-specific demethylase 5 (KDM5), particularly KDM5B (JARID1B), reported to be useful for the treatment of cancer, anxiety disorder, schizophrenia, viral infection, bipolar disorder, autism, Alzheimer's and Huntington's diseases, among others.
CSPC Megalith Biopharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising a humanized monoclonal antibody targeting nectin-4 covalently linked to cytotoxic agents through a linker. They are reported to be useful for the treatment of cancer.
RSS
